Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2023 | VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study | ANNALS OF ONCOLOGY |